Microdialysis: an in vivo approach for measuring drug delivery in oncology Martin BrunnerMarkus Müller Review Article 23 May 2002 Pages: 227 - 234
Cimicifuga racemosa: a systematic review of its clinical efficacy Francesca BorrelliEdzard Ernst Review Article 07 June 2002 Pages: 235 - 241
Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist Paul L. van GiersbergenFrédéric BodinJasper Dingemanse Pharmacokinetics and Disposition 23 May 2002 Pages: 243 - 245
The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects R. YatesM. TatenoJ. Kemp Pharmacokinetics and Disposition 25 May 2002 Pages: 247 - 252
Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach M. Meyer-BarnerI. MeinekeC. Gleiter Pharmacokinetics and Disposition 07 June 2002 Pages: 253 - 257
Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline Sanna PalovaaraMarkku AnttilaKari Laine Pharmacokinetics and Disposition 22 May 2002 Pages: 259 - 263
Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole) Karin HedenmalmOlav Spigset Pharmacoepidemiology and Prescription 06 June 2002 Pages: 265 - 274
A Swedish case-control network for studies of drug-induced morbidity – acute pancreatitis Kerstin B. BlomgrenAnders SundströmBengt-Erik Wiholm Pharmacoepidemiology and Prescription 07 June 2002 Pages: 275 - 283
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study Sebastian SchneeweissJoerg HasfordJerry Avorn Pharmacoepidemiology and Prescription 12 June 2002 Pages: 285 - 291
Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands G. 't JongP. van der LindenJ. van den Anker Pharmacoepidemiology and Prescription 15 June 2002 Pages: 293 - 297
Cyclosporin A pharmacokinetics in a patient with psoriasis and obesity, presenting with high levels of low-destiny lipoprotein Tomoki OkudaTsunao Oh-i Letter to the Editors 09 May 2002 Pages: 299 - 300